This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-29 and is reviewed periodically as new material appears.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
== Lexicology == The Latin term impotentia coeundi describes simple inability to insert the penis into the vagina; it is now mostly replaced by more precise terms, such as erectile dysfunction (ED). The study of ED within medicine is covered by andrology, a sub-field within urology. Research indicates that ED is common, and it is suggested that approximately 40% of males experience symptoms compatible with ED, at least occasionally. The condition is also on occasion called phallic impotence. Its antonym, or opposite condition, is priapism.
=== CaMPARI === Also at the Janelia Research Campus, a new fluorescent molecules known as CaMPARI (calcium-modulated photoactivatable ratiometric integrator) was developed using EosFP. The permanent green to red conversion signal was coupled with a calcium-sensitive protein, calmodulin, so that color change in the fusion construct depended on the release of calcium accompanied by neural activity. CaMPARI is able to permanently mark neurons that are active at an any time and can also be targeted to synapses. This visualization is possible across a wide amount of brain tissue as opposed to the limited view available with using a microscope. It also allows for the visualization of neural activity during complicated behaviors as the organism under study is allowed to move freely, rather than under a microscope. It also allows for the observation of neurons during specific behavior periods. CaMPARI has, thus far, been used to label active neural circuits in mice, zebrafish and fruit flies.
=== Absorption by the State Department === On March 28, 2025, U.S. Secretary of State Marco Rubio notified Congress that USAID would be dissolved and absorbed into the U.S. State Department, stating that USAID had been fiscally irresponsible and strayed from original mission. He argued, "Unfortunately, USAID strayed from its original mission long ago. As a result, the gains were too few and the costs were too high." Since July 1, 2025, USAID's operations have ceased and U.S. foreign assistance has now been administered by the U.S. State Department. In connection with this effort, 83% of USAID programs were cancelled. 94% of staff were laid off. Representative Jim Himes (D-Conn.), the top Democrat on the House Intelligence Committee, stated as an example of what he viewed as abrupt and irresponsible cost-cutting: “Thanks to DOGE, the men we paid to guard the most vicious ISIS terrorists in the world in Syria walked off the job.” USAID employees were not automatically transferred. Instead, the State Department is engaging in a “separate and independent hiring process.”
Prucalopride, sold under brand names Resolor and Motegrity among others, is a medication acting as a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements. Prucalopride was approved for medical use in the European Union in 2009, in Canada in 2011, and in the United States in December 2018.
Playing the Cincinnati Reds on July 20, 2003, Bagwell hit two home runs for the 400th of his career off Danny Graves, becoming the 35th player in MLB history to do so. ESPN's "The List" ranked Bagwell as the second-most underrated athlete of the top four North American professional sports leagues in August 2003, and Biggio third.
Sources: en.wikipedia.org
The problem of the diesels causing a vacuum in the submarine when the head valve is submerged still exists in later model diesel submarines but is mitigated by high-vacuum cut-off sensors that shut down the engines when the vacuum in the ship reaches a pre-set point. Modern snorkel induction masts have a fail-safe design using compressed air, controlled by a simple electrical circuit, to hold the "head valve" open against the pull of a powerful spring. Seawater washing over the mast shorts out exposed electrodes on top, breaking the control, and shutting the "head valve" while it is submerged. US submarines did not adopt the use of snorkels until after WWII.
Some of the heavier elements in the periodic table may be revealed to have yet-undiscovered isotopes with longer lifetimes than those listed here. About 338 nuclides are found naturally on Earth. These comprise not only the 286 primordials, but also include about 52 shorter-lived isotopes that either are daughters of primordial isotopes (such as radium from uranium) or are made by energetic natural processes, such as carbon-14 made from atmospheric nitrogen by bombardment from cosmic rays.
=== Parathyroid hormone-related protein === Parathyroid hormone-related protein (PTHrP) is a multifunctional peptide that plays a crucial role in calcium homeostasis, vascular regulation, and cellular proliferation. While it is traditionally recognized as a secreted factor that binds to surface receptors, PTHrP also functions as an intracrine regulator within cardiac cells. Its intracrine actions influence myocardial growth, vascular remodeling, and responses to stress, making it a key factor in cardiovascular physiology and pathology.
The Mystery of the Yellow Room by Leroux opened 14 February 1912 in Paris, and a translation by Hannaford Bennett played 93 performances at the St James Theatre in London in 1920. Sybil Thorndike played Mathilde. Film and TV:
Sources: en.wikipedia.org
== Ligands and potential ligand-based disease related activities == The functions of FPR3 and the few ligands which activate it have not been fully clarified. Despite its homology to FPR1, FPR3 is unresponsive to many FPR1-stimulating formyl peptides including FMLP. However, fMMYALF, a N-formyl hexapeptide derived from the mitochondrial protein, NADH dehydrogenase subunit 6, is a weak agonist for FPR3 but >100-fold more potent in stimulating FPR1 and FPR2. F2L is a naturally occurring acylated peptide derived from the N-terminal sequence of heme-binding protein 1 by cathepsin D cleavage that potently stimulates chemotaxis through FPR3 in monocytes and monocyte-derived dendritic cells. F2L thereby may be a pro-inflammatory stimulus for FPR3. Similar to FPR2 (see FPR2 section), FPR3 is activated by humanin and thereby may be involved in inhibiting the inflammation occurring in and perhaps contributing to Alzheimer's disease.
Pituicytes from the posterior pituitary are glial cells with characteristics in common to astrocytes. Tanycytes in the median eminence of the hypothalamus are a type of ependymal cell that descend from radial glia and line the base of the third ventricle. Connective tissue is found in between other tissues and comprises connective tissue proper and special connective tissue. Most types of connective tissue consists of three main components: elastic and collagen fibers, ground substance, and cells. Connective tissue membranes include the synovial membrane, which lines the inner surface of capsules of synovial joints, tendon sheaths, and synovial bursas. Connective tissue proper includes loose (or areolar) and dense (regular and irregular) connective tissue. Adipose (Latin adeps, adip-, fat) and reticular connective tissue are regarded by older sources as forms of loose connective tissue alongside areolar tissue, while some newer sources have termed them as forms of special connective tissue. Special connective tissue includes supportive connective tissue (bone and cartilage) and fluid connective tissue (blood and lymph). Epithelial tissue are protective tissue that form the glands and outermost layer of many organs, including the skin (epidermis), internal organs (mesothelium), blood and lymphatic vessels (endothelium), as well as specialised organs (e.g. olfactory, respiratory, intestinal, transitional, vaginal, germinal (female), and germinal (male) epithelia).
In order to be used for pharmaceutical and biotechnology applications for production of licensed human and veterinary health care products it must comply with the specification of the following pharmacopeias monographs:
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.